

# 1 **The Dynamic Genetic Atlas of 122 Gestational**

## 2 **Phenotypes**

3

4 Siyang Liu<sup>1\*#</sup>, Hao Zheng<sup>1,2,3\*</sup>, Yuqin Gu<sup>1,3\*</sup>, Zijing Yang<sup>1,2\*</sup>, Yanhong Liu<sup>1</sup>, Yuandan

5 Wei<sup>1,3</sup>, Xinxin Guo<sup>1</sup>, Yanchao Chen<sup>1</sup>, Liang Hu<sup>2</sup>, Xiaohang Chen<sup>2</sup>, Fuquan Zhang<sup>3</sup>,

6 Guo-Bo Chen<sup>4</sup>, Xiu Qiu<sup>5</sup>, Shujia Huang<sup>5#</sup>, Jianxin Zhen<sup>3#</sup>, Fengxiang Wei<sup>2,6#</sup>

7 1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen,

8 Guangdong 518107, China

9 2. The Genetics Laboratory, Longgang District Maternity and Child Healthcare

10 Hospital of Shenzhen City, Shenzhen, Guangdong, 518172, China

11 3. Central Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen,

12 Guangdong 518102, China

13 4. Center for Productive Medicine, Department of Genetic and Genomic Medicine,

14 Clinical Research Institute, Zhejiang Provincial People's Hospital, People's

15 Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China

16 5. Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center,

17 Guangzhou Medical University, Guangzhou, 510623, China

18 6. Longgang Maternity and Child Institute of Shantou University Medical College,

19 Shenzhen, Guangdong, 518172, China

20 \*: Those authors contribute equally as co-first authors

21 #: Correspondence can be addressed to

- 22 Siyang Liu [liusy99@mail.sysu.edu.cn](mailto:liusy99@mail.sysu.edu.cn)
- 23 Shujia Huang [shujia.huang@bigcs.org](mailto:shujia.huang@bigcs.org)
- 24 Jianxin Zhen [jxzhen@qq.com](mailto:jxzhen@qq.com)
- 25 Fengxiang Wei [haowei727499@163.com](mailto:haowei727499@163.com)
- 26

## 27 **Abstract**

28 The gestational period, spanning approximately 40 weeks from fertilization to birth, is  
29 pivotal in human reproduction. Monitoring the health of pregnant women and  
30 newborns during this period involves systematic prenatal and postpartum  
31 examinations, guided by indicators established under the national medical insurance  
32 system, collectively termed gestational phenotypes. However, our understanding of  
33 the genetic basis of these phenotypes and their intricate relationship with maternal  
34 long-term health outcomes remain markedly limited. We conducted comprehensive  
35 genetic investigations into 122 gestational phenotypes among 121,579 Chinese  
36 pregnancies. These phenotypes included anthropometric metrics, comprehensive  
37 blood biomarker measurements, and common gestational complications and outcomes.  
38 We identified 3,845 genetic loci, 1,385 of which are novel. Our analyses revealed  
39 gestation-specific genetic effects, ranging from proportion 0% to 100% for 23  
40 phenotypes, highlighting genes and pathways predominantly enriched in response to  
41 hormones, growth and immune function. Longitudinal trajectory genome-wide  
42 association study (GWAS) analyses of repeated measures across 24 complete blood  
43 cell phenotypes revealed that 17.8% of the genetic variants exhibited significant  
44 interactions with gestational timing across five gestational and postpartum periods.  
45 Two-sample univariable and multivariable Mendelian Randomization (MR) analyses  
46 of 220 mid- and old-age phenotypes suggested causal associations between  
47 gestational phenotypes and the risk of chronic diseases in later life. These findings  
48 provide initial insights into the genetic foundations of human gestational phenotypes  
49 and their relationship with long-term health, laying a basis for advanced population  
50 health during gestation.

51

52

## 53 **Introduction**

54 Women's reproductive, maternal, newborn, child, and adolescent health are  
55 fundamental aspects of human health development and the key drivers of future  
56 population and social progress<sup>1,2</sup>. Amid the global trends of population aging and  
57 declining fertility rates<sup>3,4</sup>, maternal and child health has increasingly emerged as a  
58 critical global public health concern. Particularly noteworthy is the gestational period,  
59 starting from fertilization, to birth over approximately 40 weeks, is a crucial phase  
60 during which the developing organism undergoes substantial growth and  
61 differentiation, while the pregnant individual experiences various physiological  
62 changes to support the fetus<sup>5,6</sup>. Given the importance of this period, the health of  
63 pregnant women and newborns is monitored through a set of systematic and timed  
64 prenatal and postpartum examinations manipulated via the national medical insurance  
65 system. These indicators encompass anthropometric metrics, a series of blood and  
66 urine measurements and prenatal tests, forming the basis for diagnosing pregnancy  
67 disorders and forecasting birth outcomes, collectively making up the gestational  
68 phenotypes (**Fig. 1 and Supplementary Table 1**).

69  
70 Despite the critical nature of the gestation period, the genetic underpinnings  
71 underlying the gestational phenotypes and their connections to later age health  
72 outcomes remain poorly understood. Of the 122 gestational phenotypes, only 29 have  
73 been explored in previous GWAS studies (**Supplementary Table 1**), and 11 were  
74 part of our earlier work<sup>7-9</sup>. While extensive genetic studies have been conducted on a  
75 variety on various quantitative phenotypes in the general population<sup>10,11</sup>, few have  
76 addressed the distinct genetic basis of phenotypes during the gestation<sup>8,9,12</sup>, and the  
77 time-dependent genetic effects during this period remain largely unknown.  
78 Additionally, despite observational studies have linked gestational status to maternal  
79 older age health status<sup>13-16</sup>, evaluations of the causal effects of the spectrum of  
80 gestational phenotypes, which usually collected earlier in life, on later age health

81 status have not yet been achieved, hindering the potential for early screening of  
82 diseases for women typically aged 20 to 40.

83

84 To address this gap, we collected data on 122 prenatal and postnatal screening  
85 indicators and non-invasive prenatal test (NIPT) sequencing data from 121,579  
86 unrelated pregnant women (mean age  $30 \pm 4$ ). We posed the following questions: (1)  
87 What are the genetic determinants for these gestational phenotypes and what is their  
88 heritability? (2) Do pregnancy-specific genetic effects exist, and which genes exhibit  
89 these effects? (3) Are there gene-by-environment ( $G \times E$ ) interactions for the genetic  
90 loci associated with gestational phenotypes? (4) What are the causal relationships  
91 between gestational phenotypes and maternal long-term health? To address these  
92 questions, we conducted a large-scale genome-wide association study (GWAS) using  
93 our developed analytical protocol<sup>7,17</sup>, constructing an atlas of quantitative and  
94 qualitative trait loci and replicating our findings in external cohorts. We investigated  
95 patterns of genetic loci with differential effects during pregnancy and non-pregnancy  
96 using a Bayesian clustering algorithm, and examined  $G \times E$  effects through repeated  
97 sampling of the same phenotypes during pregnancy using regression models. Finally,  
98 we used our atlas to estimate potential causal relationships between gestational  
99 phenotypes and 220 phenotypes in BioBank Japan (mean age 63 years), mimicking an  
100 impact of the gestational phenotypes over the long-term health outcomes<sup>10</sup> (**Fig. 1**).

101

## 102 **Results**

### 103 **Study design**

104 We collected NIPT sequencing data and 122 comprehensive pregnancy screening  
105 measurements, including biomarkers and electronic medical records, from 121,579  
106 Chinese pregnancies who participated in routine obstetric examinations at two  
107 hospitals in Shenzhen City. We categorized the 88 gestational phenotypes into nine  
108 molecular test categories: Blood lipid (N=2), Glycemic (N=6), Blood routine (N=32),

109 Infection (N=14), Kidney (N=3), Liver function (N=8), Thyroid function (N=4), Tang  
110 screening (N=16) and NIPT screening (N=3) (**Fig.1, Supplementary Table 2**).  
111 Additionally, we included 34 phenotypes in three categories of electronic medical  
112 records: Basic information such as maternal height, weight, blood pressure (N=7),  
113 Gestational disorders (N=21) and Birth outcomes (N=6) (**Fig. 1, Supplementary**  
114 **Table 3**). Sample sizes for each phenotype ranged from 12,024 (gestational diabetes  
115 mellitus with medication in Glycemic) to 115,872 (trisomy 18 risk score in NIPT  
116 screening). The distribution of all quantitative gestational phenotypes and the  
117 prevalence of common gestational comorbidities were highly consistent between the  
118 two hospitals (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

119  
120 All participants underwent NIPT as part of standard prenatal screening in Shenzhen.  
121 We applied our estimated protocol to infer and impute genotypes, estimate family-  
122 relatedness, infer population structure, and conduct GWAS. More details about the  
123 analyses are provided in the **Methods** section.

124

### 125 **3,845 genetic associations with 122 gestational phenotypes**

126 Using the collected phenotype data and NIPT genotypes, we performed GWAS for  
127 the 122 gestational phenotypes from Baoan and Longgang hospitals, respectively,  
128 followed by a fixed-effect meta-analysis across 12.6 million genetic markers  
129 (**Supplementary Table 6**). Linkage disequilibrium (LD) score intercepts were  
130 between 0.94 and 1.10 for all 122 phenotypes (**Supplementary Table 7**), which  
131 suggested that population structure in our analysis was well controlled. Besides the  
132 conventional genome-wide significant threshold ( $P < 5 \times 10^{-8}$ ), we set a stricter study-  
133 wide significant threshold to  $P = 4.1 \times 10^{-10}$  ( $P < 5 \times 10^{-8} / 122$ ) after Bonferroni  
134 correction for multiple testing. After GCTA conditional and joint analysis<sup>18</sup>, we  
135 identified 4,309 independent signals in 3,242 loci associated with at least one  
136 phenotypes ( $P < 5 \times 10^{-8}$ ) among nine categories (**Supplementary Table 8**), where

137 2,942 signals in 1,999 loci reached study-wide significance ( $P < 4.1 \times 10^{-10}$ ) (**Fig. 2,**  
138 **Supplementary Table 9**). The highest number of loci were found in the blood routine  
139 category among all the categories, and the phenotype with the highest number of loci  
140 was platelet-large cell ratio (P\_LCR) (**Fig. 2, Supplementary Table 9**). Within the  
141 three categories of basic information, birth outcomes and gestational disorders, we  
142 found 367 independent signals in 279 loci ( $P < 4.1 \times 10^{-10}$ ) and 718 independent  
143 signals in 603 loci ( $P < 5 \times 10^{-8}$ ) (**Supplementary Table 10-11**).

144  
145 Genetic effect estimations are highly consistent between the two hospitals with  
146 squared Pearson's correlation coefficient  $R^2$  greater than 0.76 for nine categories of  
147 quantitative traits and  $R^2$  greater than 0.12 for three categories of qualitative traits  
148 (**Supplementary Fig. 3**). Only 369 out of 4,309 (8.5%) loci associated with the nine  
149 categories of gestational phenotypes and 74 out of 718 (10.3%) associated with the  
150 three categories of gestational phenotypes exhibited statistical heterogeneity  
151 ( $P_{\text{het}} < 0.05$ ) (**Supplementary Table 8-11**). We also performed two replication studies  
152 comparing genetic effect estimates with independent cohorts to evaluate the  
153 robustness of effect estimates in our study. In replication study I, assuming maternal  
154 height is not influenced by a gestational status, we compared genetic effect estimates  
155 of maternal height-associated variants with that estimated in the Taiwan Biobank with  
156 the GWAS summary statistic for maternal height in this study<sup>19</sup>. The genetic effect  
157 estimates are highly consistent between our study and the Taiwan Biobank study with  
158  $R^2 = 0.93$  (**Supplementary Fig. 4**). There were 121 variants with  $P$  values less than  
159 the Bonferroni correction threshold ( $P < 2.79 \times 10^{-4}$ , 66.9%), and 166 variants with  $P$   
160 value less than 0.05 (91.7%) (**Supplementary Fig. 4, Supplementary Table 12**). In  
161 replication study II, we compared the genetic effects with an independent cohort  
162 (NIPT PLUS pregnancy cohort), which is our additional collection of maternal check-  
163 up data from 5,733 pregnant women (**Methods**). Using *two-sample t-test*, 4,059 of the  
164 4,804 variants of the 103 phenotypes with data in NIPT PLUS cohort had consistent

165 genetic effect size in independent cohort (84.5%) (**Supplementary Fig. 5,**  
166 **Supplementary Table 13**). Of the 3,198 variants that were study-wide significance  
167 within the study, 2,786 variants had consistent genetic effect (87.1%)  
168 (**Supplementary Table 13**). The above results indicate high fidelity of the GWAS  
169 findings and genetic effect estimates in this study.

170

### 171 **1,385 novel genetic associations**

172 Among the 122 gestational phenotypes, 29 were previously investigated among  
173 pregnant women and 70 were investigated in the general populations  
174 (**Supplementary Table 1**). After comparison with the GWAS Catalog<sup>20</sup> of previously  
175 reported associations with the same or similar phenotypes in either the pregnant or the  
176 general populations (**Methods**), 1,189 of the 3,242 loci surpassing the genome-wide  
177 threshold (**Supplementary Table 8**), and 651 of the 1,999 loci surpassing the study-  
178 wide threshold were novel among nine categories (**Supplementary Table 9**). Among  
179 the three categories, 196 of the 603 loci surpassing the genome-wide threshold, as  
180 well as 64 of the 279 loci surpassing the study-wide threshold were novel  
181 (**Supplementary Table 10-11**). Notably, 5,483 and 5,194 functional variants  
182 including missense and nonsense variants ( $P < 5 \times 10^{-8}$ ) were found for the 3,242  
183 genome-wide significant loci and the 1,999 study-wide significant loci ( $P < 4.1 \times 10^{-10}$ ),  
184 respectively (**Supplementary Table 14-15**). 256 study-wide newly discovered loci  
185 with at least one functional variant were illustrated in **Fig. 2**.

186

187 Among the 651 study-wide significant novel loci associated with the nine  
188 quantitative trait categories, 114 were associated with multiple gestational  
189 phenotypes (**Supplementary Table 16**). The genes mapped in these 114  
190 pleiotropic loci were significantly enriched in GO pathway such as response to  
191 hormones, compared to an enrichment of more basic cellular processes such as  
192 hemostasis, regulation of cell-cell adhesion for genes without pleiotropy



193 (Supplementary Fig. 6). Protein-protein interaction network (PPIN) analysis  
194 suggests that *IL6* involved in immune responses, *ESRI* related to hormone response  
195 and *IGF1* and *EGF* related to cell growth and development are the most essential  
196 hub genes (Supplementary Fig. 7, Supplementary Table 17). The *ESRI*  
197 associated with nine gestational phenotypes, is among the genetic loci with the  
198 broadest pleiotropy (Supplementary Fig. 8, Supplementary Table 16). The  
199 estrogen receptor 1, *ESRI* is a key gene for embryo implantation and affects uterine  
200 natural killer cell motility and thus vascular remodeling in early pregnancy and the  
201 placenta<sup>21-23</sup>. This is consistent with our findings of variants in *ESRI* were  
202 significantly associated with leukocytes (lymphocyte percentage (LYM\_P),  
203 monocyte absolute value (MON), neutrophils absolute value (NEUT) and white  
204 blood cell count (WBC)) during pregnancy (Supplementary Fig. 8,  
205 Supplementary Table 16). In addition, *ESRI* is first identified to be strongly  
206 associated with triglyceride (TG), oral glucose tolerance test 0 hour (OGTT0H), red  
207 blood cell count (RBC) and hematocrit (Hct) in our study. Several other genetic  
208 loci exhibiting the highest level of pleiotropy in gestational phenotypes include  
209 *ELOVL5* (encoding ELOL fatty acid elongase 5) associated with beta human  
210 chorionic gonadotropin (FHCG), pappalysin (PAPP) and Tang screening scores of  
211 Trisomies 21 and 18, *SLC35A1* (solute carrier family 35 member A1) associated  
212 with FHCG, Tang screening score of Trisomy 21 and free thyroxine (FT4) which  
213 are important for pregnancy (Supplementary Table 16).  
214  
215 We particularly examined a number of phenotypes that had been very poorly  
216 studied, such as the screening phenotypes for fetal trisomy. Combined maternal  
217 serum Tang and NIPT screening along with fetal ultrasound testing are used to  
218 screen for the risk of fetal trisomy<sup>24,25</sup>, so these phenotypes are essential for the  
219 gestational period. For the NIPT screening scores for T21, T18 and T13, we found  
220 26, 35 and 31 quantitative trait loci ( $P < 4.1 \times 10^{-10}$ ) (Supplementary Table 9,

221 **Supplementary Fig. 9**). Notably, intronic variants, eQTLs for *PANXI*, located in  
222 chromosome 11, a cell membrane factor highest expressing in human oocytes,  
223 eight-cell embryos, and the brain were significantly associated with all three scores  
224 in the NIPT screening. Abnormal Pannexin 1 (*PANXI*) has been previously linked  
225 to a type of infertility called “oocyte death” in family study<sup>26,27</sup>. In our study, all the  
226 variants associated with a decreasing *PANXI* increases the NIPT screening scores,  
227 suggesting higher trisomy risk. Meanwhile, variants near and within *PADI4*  
228 (peptidyl arginine deiminase 4) were similarly associated with these three  
229 phenotypes, and the gene is associated with neutrophil extracellular trap formation  
230 (NETosis) and is important for immune regulation during pregnancy<sup>28-30</sup>. In  
231 addition, TNF superfamily member 13b (*TNFSF13B*) and ubiquitin specific  
232 peptidase 3 (*USP3*) are associated with two of these scores, and they both play a  
233 role in the innate immune response<sup>31,32</sup>.

234

### 235 **Heritability and correlation of gestational phenotypes**

236 To characterize the heritability of the 122 phenotypes, we applied LD Score  
237 regression (LDSC)<sup>33</sup>. Among all the phenotypes, maternal serum vitamin B12 levels  
238 had the highest SNP heritability of 43.97% (**Supplementary Table 7,**  
239 **Supplementary Fig. 10**). The phenotype with lowest SNP heritability was gestational  
240 thrombocytopenia, at 0.0045% (**Supplementary Table 7, Supplementary Fig. 10**).  
241 Although the heritability of vitamin B12 in the UK Biobank (UKB) ( $h^2=0.00953$ ,  
242  $se=0.0143$ ) is low<sup>34</sup>, there is a study of white British twin women that showed a 56%  
243 heritability of serum vitamin B12<sup>35</sup>. We hypothesize that the reason for the disparity  
244 with UKB is the effect of racial differences and gender of the population.

245

246 Phenotypic and genetic correlations were calculated for a total of 88 quantitative  
247 phenotypes in nine categories put together (**Supplementary Fig. 11, Supplementary**  
248 **Table 18-19**,). The two heatmaps were basically symmetric along the red diagonal

249 line suggesting that substantial phenotypic variability derived from the genetic  
250 variability (**Supplementary Fig. 11**). Tightly correlated phenotypic domains were  
251 clustered within categories, while significant and strong genetic correlations also  
252 occur across categories.

253

### 254 **Gestation-specific genetic effect**

255 Gestational phenotypes may exhibit pregnancy-specific genetic effects distinct from  
256 the same phenotypes outside pregnancy. For 23 out of the 122 phenotypes  
257 investigated, including maternal height, we obtained GWAS data in a non-pregnant  
258 cohort from the Taiwan Biobank (n = 92,615, age 30-70, southern Chinese ancestry)  
259 <sup>19</sup>. Genetic correlations for the same phenotype between the two datasets are all  
260 significant ranging from 0.18 to 0.94 (**Supplementary Table 20**). Correlations of  
261 genetic effect of NIPT lead SNPs are high between our study and the Taiwan Biobank  
262 study with genetic effect  $R^2$  ranging from 0.001 to 0.99 (**Supplementary Fig. 12**,  
263 **Supplementary Table 21**). 900 genetic signals were present with study-wide  
264 significance for the 23 phenotypes and 792 signals have genetic effect information in  
265 both our and the Taiwan studies (**Supplementary Table 22**).

266

267 We then applied a Bayesian clustering algorithm<sup>36</sup> combined with colocalization  
268 analysis to explore whether there exists genetic effects that are predominantly  
269 influenced by pregnancy compared to non-pregnancy population. Model parameters  
270 are detailed in **Supplementary Table 23 and Methods**. Genetic loci associated with  
271 each of the gestational trait were categorized into two groups: general and pregnancy-  
272 specific, with the remaining loci denoted as unclassified. In total, we have identified  
273 138 genetic signals exhibiting pregnancy specific genetic effects (**Supplementary Fig.**  
274 **13, Supplementary Table 24**). The general variants indicates that the genetic effects  
275 were shared with non-pregnancy phenotypes, and pregnancy-specific cluster indicates  
276 the ones dominated by mainly gestational phenotypes. In total, we found 138 out of

277 the 792 signals exhibiting pregnancy-specific effects (17.4%), while 381 signals  
278 demonstrating shared genetic effect (48.1%) and 273 remains uncertain (34.5%).  
279 When ranking these 23 phenotypes by the proportion of pregnancy-specific loci  
280 among all loci, alpha fetoprotein levels (AFP\_S2) or its adjusted form, the alpha-  
281 fetoprotein multiples-of-median (AFPMOM\_S2) in second trimester screening have  
282 the highest proportion of variants exhibiting pregnancy-specific genetic effects,  
283 followed by two biomarkers for liver function including alanine transaminase (ALT)  
284 and albumin (ALB) (**Fig. 3A, Supplementary Table 24**). Contrastly, the lowest  
285 proportion of pregnancy specific variants were observed for maternal height and first  
286 systolic blood pressure measurements, consistent with our perception that pregnant  
287 women's height is largely unchanged during pregnancy and blood pressure stays  
288 stable in early pregnancy.

289  
290 Pathway enrichment analyses of the pregnancy-specific, general and overall genetic  
291 loci were summarized in **Supplementary Fig. 14**. We further conducted a pathway  
292 enrichment analyses using genes falling within the pregnancy-specific effect and the  
293 general effect clusters to test whether some pathways may significantly differ between  
294 the two clusters of genes (two-tailed chisq or fisher exact test,  $P < 0.05$ ) (**Fig. 3B,**  
295 **Supplementary Table 25**). Among these top 20 significant pathways for the  
296 pregnancy-specific genetic loci, there are a variety of pathways that have significantly  
297 different gene proportion on both sides, such as the retinoid metabolism and transport,  
298 Wnt signaling pathway and pluripotency and regulation of protein catabolic process  
299 that only contains pregnancy-specific loci (**Fig. 3B**). In addition, pathways that  
300 demonstrated nominally significance include GO pathways of responses to hormone,  
301 glucose homeostasis and regulation of lymphocyte proliferation; KEGG pathways of  
302 breast cancer, WikiPathways of pathways in cancer and adipogenesis and Reactome  
303 gene sets of signaling by nuclear receptors (**Supplementary Table 25**). PPI network  
304 hub gene analyses weighting the genes by degree suggests that the most

305 distinguishing hub genes are similar to the genes that were associated with multiple  
306 gestational phenotypes, including the estrogen receptor (*ESR1*), insulin like growth  
307 factor 1 (*IGF1*) and interleukin 6 (*IL6*) (**Supplementary Fig. 15, Supplementary**  
308 **Table 26**). These findings suggests that hormone, growth and development mediators  
309 and immune regulations are playing an essential role for starting the gestation process.  
310

### 311 **G (genetics) by T (time) interaction across gestation and postpartum** 312 **period**

313 Among the 122 gestational phenotypes, the 24 phenotypes belonging to the blood  
314 routine category assayed by the complete blood count (CBC)<sup>37,38</sup> are repeatedly  
315 assayed for a median number of 5 to 6 measurements in each of the two hospitals  
316 (**Supplementary Fig. 16-17, Supplementary Table 27**), offering us an opportunity  
317 to understand the patterns and biological meaning of potential longitudinal time-  
318 varying genetic effect.

319  
320 The changing trends of these 24 phenotypes during pregnancy were largely similar  
321 between the two hospitals (**Supplementary Fig. 18-19**). Among the leukocyte-related  
322 phenotypes, white blood cell (WBC), neutrophil counts (NEUT), and neutrophil  
323 percentages (NEU\_P) increased significantly during pregnancy. In addition,  
324 lymphocyte (LYM) levels decreased, monocyte (MON) levels increased, eosinophils  
325 (EOS) were essentially unchanged and basophils (BASO) fluctuated at average levels.  
326 Red blood cell counts (RBC), hemoglobin (HGB) levels, hematocrit (Hct) and platelet  
327 count (PLT) have a significant downward trend during pregnancy. All CBC  
328 phenotypes changed greatly in the delivery and postpartum period, tending to return  
329 to pre-pregnancy levels.

330  
331 We investigated the longitudinal time-varying genetic effect following two steps. First,  
332 we applied TrajGWAS<sup>39</sup> to identify genetic variants affecting the phenotypic mean

333 variability across the 24 CBC gestational phenotypes for each hospital, respectively.  
334 By default, TrajGWAS<sup>39</sup> will also compute the effect of genetic variants affecting the  
335 within-subject variability. Genetic variants affecting phenotypic mean and within-  
336 subject variability ( $\beta_g$  and  $\tau_g$  significant genetic variants) are shown in the  
337 **Supplementary Fig. 20-27**. In total, we identified 645 variants associated with the  
338 phenotypic mean reaching a genome-wide significance threshold in both hospitals ( $P$   
339  $< 5 \times 10^{-8}$ ). Secondly, we included a genotype dosage and gestational day interaction  
340 term in the above TrajGWAS regression model for each hospital, testing the statistical  
341 significance of the interaction effect size, similar to a locus-based genetic-by-time  
342 ( $G \times T$ ) analysis (**Methods**). After integrating the two hospital statistics via inverse-  
343 weighted variance fixed effect meta-analysis, 115 out of 645 the variants (17.8%)  
344 demonstrated significant interaction effect with gestational days ( $P < 5 \times 10^{-8}$ )  
345 (**Supplementary Table 28**), while the rest of the 530 variants only affected the  
346 phenotypic mean level but the interaction effects were not significant  
347 (**Supplementary Table 29**). Among the 23 phenotypes, the percentage of variants  
348 with significant  $G \times T$  effects ranged from 5.4% to 47.8% (**Supplementary Table**  
349 **30**).

350  
351 To explore how genetic variants specifically change during the first, second, third  
352 trimesters of pregnancy, delivery, and postpartum period, we performed localized  
353 association studies of these 115 variants (**Methods, Supplementary Table 31**) and  
354 found 79 out of the 115 variants exhibited non-overlapping 95% CIs for genetic effects  
355 in at least two of the five periods (**Supplementary Table 31, Supplementary Fig.**  
356 **28**). Therefore, we confirm that 79 out of the 645 variants (12.2%) demonstrated  
357 substantial and significant changes of genetic effects across the gestation and  
358 postpartum period. The 25 variants with the most significant  $G \times T$  interaction effects  
359 were demonstrated in **Fig. 4A**. 22 out of these 25 variants have strong expression  
360 quantitative trait loci (eQTL) information (**Supplementary Table 31**). Taking the

361 gestational WBC (leukocyte) count as an example, the WBC count steadily increased  
362 since the first trimester and reached its highest in the 3<sup>rd</sup> trimester and delivery (**Fig.**  
363 **4B**). Among the 27 variants associated with WBC, eight variants (29.6%) exhibiting  
364 significant  $G \times T$  interaction. Among the eight variants, rs2270401 (17q21.1), a  
365 strong eQTL for *GSDMA*, exhibited the most significant  $G \times T$  interaction effect,  
366 with genetic effects varied substantially across the five periods (first trimester:  
367  $\beta=0.270$ ,  $P=6.44 \times 10^{-491}$ ; second trimester:  $\beta=0.396$ ,  $P=1.62 \times 10^{-1223}$ ; third trimester:  
368  $\beta=0.388$ ,  $P=2.27 \times 10^{-1021}$ ; delivery:  $\beta=0.257$ ,  $P=2.06 \times 10^{-152}$ ; postpartum:  $\beta=0.122$ ,  
369  $P=6.48 \times 10^{-60}$ ) (**Fig. 4C, Supplementary Table 31**). The genetic effect of the  
370 rs2270401-A allele was 3.33 times greater in the second trimester than in the  
371 postpartum period. Genetic effect of the other seven loci also demonstrated a U-  
372 shaped change across the five period (**Supplementary Fig. 28**). The WBC phenotypic  
373 and genetic effect changes of the eight loci suggest these loci may play an essential  
374 role in the rapid growth of leukocytes during pregnancy and postpartum.  
375  
376 We extracted genetic variants with significant versus non-significant genetic and  
377 environmental interactions for enrichment analyses. Gene enrichment analysis for  
378 each category of variants were summarized in **Supplementary Fig. 29**. In a chisq and  
379 fisher exact test for testing significant difference of pathways with interaction effect  
380 and those without, we found pathways enriched in regulation of phagocytosis,  
381 engulfment, prefoldin mediated transfer of substrate to CCT/TriC, Heparan  
382 sulfate/heparin (HS-GAG) metabolism, Gap junction, nerve development and lipid  
383 modification (**Fig. 4D, Supplementary Table 32**). Different from the genes  
384 harboring gestation-specific genetic effects, PPI network hub gene analyses weighting  
385 the genes by degree suggests that the most distinguishing hub gene is Epidermal  
386 Growth Factor (*EGF*) involved in cell growth and development and the GATA  
387 binding protein 2 (*GATA2*) which involved in hematopoietic development  
388 (**Supplementary Fig. 30, Supplementary Table 33**). This suggests that alterations

389 in the genetic effects of variants affecting blood cell levels during pregnancy are more  
390 related to changes in cell activation and cytokines in pregnant women.

391

### 392 **Causal relationship with older-age phenotypes**

393 To explore whether gestational phenome may influence or correlated with the  
394 occurrence of chronic diseases in mothers in the distant future, we first estimated  
395 causal effects of the 122 gestational phenotypes on 220 phenotypes examined in the  
396 BioBank Japan Study (BBJ)<sup>10</sup> using two-sample, inverse variance weighted,  
397 bidirectional MR and four additional two-sample approaches as sensitivity analyses.  
398 After MR-PRESSO elimination of outliers<sup>40</sup>, 73 significant potential causal  
399 relationships were found for the 122 gestational phenotypes, using FDR  $q$ -value less  
400 than 0.01 as false discovery rate (FDR) threshold with 1,764 non-collinear phenotypic  
401 pairs and excluding Cochran's Q statistic or pleiotropy  $P$ -value less than 0.05, and  
402 these causal relationships were not significant in the reverse MR (Methods). The  
403 bidirectional causal effect estimates were presented in a network view in **Fig. 5A**,  
404 with the forward MR effect estimates of 88 molecular phenotypes presented in **Fig.**  
405 **5B and Supplementary Table 34** and the forward MR effect estimates of the other  
406 34 phenotypes presented in **Supplementary Fig. 31 and Supplementary Table 35**.

407

408 We identified numerous previously known and unidentified potential causal  
409 associations. Genetically predicated higher gestational BMI contributes to the most of  
410 the older-age disorders and phenotypes in our study. It increasing liability of 13 older-  
411 age disorders or phenotypes with the largest effects observed on chronic renal failure  
412 ( $OR$  [95%CI]: 1.68 [1.42-2.00]), followed by several cardiovascular disorders such as  
413 myocardial infarction, peripheral artery disease, chronic heart failure, unstable angina  
414 pectoris, type 1 diabetes and cholelithiasis as well as five medication use of drugs and  
415 three physical phenotypes, while gestational BMI slightly decreasing liability of two



416 older-age disorders including pneumothorax and pulmonary tuberculosis (**Fig. 5A,**  
417 **Supplementary Fig. 31 and Supplementary Tables 35**).

418

419 In addition, our MR results suggest contribution of gestational blood lipid and  
420 glycemic biomarkers causally associated with older-age disorders. For example,  
421 genetically predicted elevated triglyceride levels in pregnant women is associated  
422 with an increased risk of taking certain medications, such as the medication use of  
423 antithrombotic agents (*OR* [95%CI]: 1.09 [1.06-1.12],  $P=1.24\times 10^{-11}$ ) (**Fig. 5C,**  
424 **Supplementary Table 34**). In addition, genetically predicted elevated 1h blood  
425 glucose levels on the oral glucose tolerance test (OGTT1H) in pregnant women  
426 increase the risk of peripheral arterial disease (PAD) (*OR* [95%CI]: 1.24 [1.13-1.37],  
427  $P=1.24\times 10^{-5}$ ) (**Fig. 5D, Supplementary Table 34**), consistent with prior report of  
428 glucose abnormalities as a risk factor for PAD<sup>41</sup>. Moreover, elevated levels of  
429 genetically predicted OGTT1H also increase the risk of cataract (*OR* [95%CI]: 1.15  
430 [1.09-1.21],  $P=3.21\times 10^{-8}$ ) (**Supplementary Table 34**), which is in accordance with  
431 the results of the animal model<sup>42</sup>.

432

433 Furthermore, our results also show that genetically increased infections increase  
434 certain disease liability. For instance, genetically increased gestational hepatitis B  
435 core antibody positive (HBcAb) increases the risk of gastric cancer (*OR* [95%CI]:  
436 1.12 [1.06-1.19],  $P=1.06\times 10^{-4}$ ), chronic hepatitis B infection (*OR* [95%CI]: 1.31  
437 [1.15-1.49],  $P=5.27\times 10^{-5}$ ) and hepatic cancer (*OR* [95%CI]: 1.24 [1.13-1.37],  
438  $P=5.02\times 10^{-6}$ ) (**Fig. 5A, Supplementary Table 34**), revealing a potential causal  
439 relationship between hepatitis B infection observed during pregnancy and  
440 extrahepatic cancers. Moreover, genetically predicted quantitative levels of  
441 cytomegalovirus IgG (CMV\_IgG\_quan) were found to be associated with an  
442 increased risk of some cardiac diseases (angina pectoris: *OR* [95%CI]: 1.31 [1.16-  
443 1.49],  $P=1.28\times 10^{-5}$ ; stable angina pectoris: *OR* [95%CI]: 1.27 [1.16-1.40]; medication

444 use vasodilators used in cardiac diseases: *OR* [95%CI]: 1.26 [1.15-1.38]). This is  
445 consistent with previous studies suggesting increased exposure to cytomegalovirus  
446 infection is related to coronary artery and vascular atherosclerotic diseases<sup>43,44</sup>. More  
447 broadly, we found that genetically predicted increases in BMI during pregnancy were  
448 associated with an increased risk of developing a variety of diseases, such as chronic  
449 kidney failure (*OR* [95%CI]: 1.68 [1.42-2.00]) and myocardial infarction (*OR*  
450 [95%CI]: 1.26 [1.17-1.35]) (**Fig. 5A, Supplementary Table 34, Supplementary Fig.**  
451 **31**). In general, a less superior physiological state during pregnancy is likely to  
452 threaten the future health of the woman.

453  
454 The causal impact of the gestational phenotypes (collected from pregnancy women  
455 with mean age of 30) may directly contribute to the later-age phenotypes (collected  
456 from BBJ with ages ranging from 30 to 70) or the causal effect may be mediated  
457 through the same phenotypes in a middle age period. To understand this process, we  
458 utilized the previously analyzed IVs with pregnancy-specific and shared effects with  
459 the 23 phenotypes shared with the Taiwan Biobank, we added GWAS data from the  
460 Taiwan Biobank as a second exposure and conducted a multivariable MR (MVMR).  
461 Using FDR  $q$  value as the threshold of significance (NIPT effect  $q < 0.01$ ), we  
462 identified a total of 45 significant causal effects of the gestational phenotypes on the  
463 later-age outcomes even after adjusting for the genetic effects of the exposures in the  
464 Taiwan Biobank. Among these, 40 effects have a  $q$  value  $> 0.05$  in the Taiwan dataset  
465 or having an opposite genetic effect compared to ones with the gestational phenotypes  
466 suggesting substantial direct causal effects on the outcomes. The remaining 5 effects  
467 have a nominally significant  $P$  and consistent effect direction in the Taiwan dataset,  
468 indicating less strong direct causal effects of the gestational phenotypes on the later  
469 age phenotypes (**Supplementary Table 40, Supplementary Fig. 32**). In addition,  
470 there are 97 effects having a  $q$  value  $< 0.01$  for the Taiwan while having an opposite  
471 beta direction or a  $q$  value  $> 0.05$  in the NIPT dataset, suggesting that the NIPT

472 effects on the outcome is primarily dominated by the middle and older age genetic  
473 effects. Among the 40 out of the 143 effects (28.0%) with potential direct causal  
474 effects, notable relationships include genetically predicted gestational AFP and  
475 AFPMOM in the second trimesters is negatively associated with atopic dermatitis and  
476 all types of white blood cell, while it is positively associated with thyroid disorders  
477 such as Grave disease, Hashimoto thyroiditis as well as medication use thyroid  
478 preparations, chronic sinusitis, Type 2 diabetes and medication use drugs in diabetes  
479 (**Supplementary Fig. 32 A-B, Supplementary Table 40**). In addition, genetically  
480 predicted albumin during pregnancy is negatively associated with chronic hepatitis B  
481 infection and cirrhosis. AST and RBC from NIPT datasets are causally associated  
482 with the related blood cell information in the BBJ (**Supplementary Fig. 32 C,**  
483 **Supplementary Table 40**). We also compared the results of univariate MR between  
484 the 23 gestational phenotypes and the Taiwanese phenotype, and the results have high  
485 consistency with an  $R^2$  of 0.79, consistent with the above statistics where the majority,  
486 namely 97 versus 45 of the gestational phenotypic effects on outcomes through older-  
487 age phenotypes, and through direct effects (**Supplementary Fig. 33, Supplementary**  
488 **Table 41-42**).

489

## 490 **Discussion**

491 Our study represents the largest scale GWAS on gestational phenotypes to date and  
492 provides the first insight into the dynamic genetic atlas of human gestational  
493 phenotypes and their causal associations with older-age health conditions. Using  
494 obstetric and NIPT genotype data from 121,579 pregnant women, we identified 3,845  
495 genome-wide significant loci, of which 1,385 loci were novel to this study and the  
496 majority of which consists of at least one function variant. More than 84.5% of the  
497 genetic associations were replicated in independent cohorts. Genes associated with  
498 multiple gestational phenotypes are enriched in response to hormones, compound  
499 biosynthetic and multi-organism reproductive processes, and PPI network analysis

500 reveals that *IL6* involved in immune responses, *ESR1* related to hormone response  
501 and *IGF1* and *EGF* related to cell growth and development are the most essential hub  
502 genes, providing the first insights into the role of immune, hormone and cell growth  
503 responses and the key gene players in gestational process from a human genetic  
504 perspective, beyond previous insights achieved via metabolome of primate pregnancy  
505 <sup>5</sup>.

506

507 Notably, the genetic atlas of gestational phenotypes is dynamic, reflecting gestation-  
508 specific  $G \times E$  and gestation time-varying  $G \times T$  interactions. Combining data from  
509 the Taiwan Biobank and using Bayesian classification analysis, we identified  
510 pervasive gestation-specific genetic effects that present in around 17.4% of the  
511 genetic associations (138/792) with 23 gestational phenotypes, ranging from ~0% for  
512 early pregnancy systolic blood pressure to 100% for alpha-fetoprotein in second  
513 trimester. Genes containing gestation-specific genetic effect exhibit a predominant  
514 enrichment in pathways involving cancer, response to hormones, lipid, vitamin and  
515 glucose metabolisms, and cell growth and development. PPI network analysis  
516 highlights *ESR1*, *IGF1* (but not *EGF*) and *IL6* as the most significant hub genes.

517

518 On the other hand, in a longitudinal trajectory GWAS analysis of repeated  
519 measurements of 24 complete blood count (CBC) phenotypes, we found significant  
520  $G \times T$  interactions present in 12.2% of the genetic variants (79/646) throughout the  
521 five gestational, delivery and postpartum periods, with hub genes as *EGF* and *CATA2*  
522 in the PPIN, and pathways enriched in regulation of cell growth activity, nerve  
523 development and lipid modification.

524

525 Conditions during gestational period were deemed as unique opportunities for early  
526 screening and prediction for late-onset chronic disease risk in women<sup>45</sup>. Our results  
527 suggest causal relationships between adverse gestational conditions and

528 cardiovascular disease, including obesity, dyslipidemia and dysglycemia. We also  
529 found that genetically predicted blood glucose abnormalities during pregnancy were  
530 associated with an increased risk of cataracts. Previous study has shown that pregnant  
531 women with gestational diabetes mellitus, even if they do not have type 2 diabetes,  
532 have an increased risk of developing cataracts<sup>46</sup>. In addition, multivariable Mendelian  
533 randomization results indicate that high AFP levels during pregnancy are likely to  
534 lead to inflammation-related diseases and diabetes, adjusted for mid-life health status.  
535 Thus, the state of pregnancy is related to women's health in the long term.

536

537 There are some limitations which are connected to future perspectives in our study.  
538 First, although the current study represents the largest GWAS for the majority of the  
539 phenotype, the current study participants are restricted to East-Asian participants, and  
540 the genetic novel discoveries may be different among non-East-Asian population.  
541 However, the study methods made available in this study provides a foundation for  
542 expanding the participants from non-East-Asian ancestry, which is promising as NIPT  
543 tests as well as pregnancy screening programs are undertaken globally around the  
544 world. The future comparisons of European and East-Asian gestational phenotypes  
545 may lead to new insights into the ethnic difference for gestational phenotypes and its  
546 relationship to offspring's health<sup>47</sup>. In addition, the cross-ancestral analysis will  
547 facilitate fine-mapping and validation of the functional variants identified in this study.  
548 Secondly, while we provide a dynamic view of the genetic atlas of the gestational  
549 phenotypes based on a robust statistical framework, unravelling 12 to 17% of  
550 gestation-specific genetic effects and time-varying genetic effects, unravelling novel  
551 genes involved in immune and hormone response, and cell-growth and development  
552 in determining phenotypic distribution specifically during gestation. How these genes  
553 may influence and modulate how gestation initializes and progresses, and how they  
554 might contribute to abnormal gestations requires further comparisons or investigations  
555 in the patient-oriented study and more in-depth mechanistic study conditioning on the

556 findings in this study. Thirdly, beyond the genetic and causal relationships between  
557 gestational phenotypes and broad human complex and older age phenotypes  
558 investigated in our study, another important investigation will be the dissection of  
559 fetal genetic and intrauterine effects on birth outcomes and offspring health  
560 conditioning on the dynamic atlas presented here and expanding birth cohort genome  
561 studies<sup>14</sup>.

562

563 The genetic discoveries in this study provides foundational insights into the dynamics  
564 of genetic landscape of the human gestational period. As we continue to expand the  
565 genomic data and methods, future efforts will be prioritized to combine the genetic  
566 information to dissect the developmental origin of children and adult disorders and for  
567 exploring health and risk prediction for women during the gestational time window.  
568 These should be conducted in global efforts.

569

570

## 571 **Methods**

### 572 **Study population**

573 From 2017 to 2022, we recruited 121,579 pregnant women who performed maternity  
574 checkups in Shenzhen Baoan Women's and Children's Hospital and Longgang District  
575 Maternity and Child Healthcare Hospital of Shenzhen City into our study. Pregnant  
576 women received prenatal and postnatal serum biomarkers testing and non-invasive  
577 prenatal testing (NIPT) in the first or second trimester or both of pregnancy. Maternal  
578 genotypes were inferred from low-depth whole-genome sequencing data generated  
579 from NIPT using our previously developed advanced methods<sup>7</sup>. In addition, we also  
580 collected basic physical measurements of participants and their babies' birth outcomes.  
581 The details of the number of participants in each test are presented in Supplementary  
582 Table (**Supplementary Table 2-3**). The age distribution of pregnant women and the

583 prevalence of some gestational comorbidities in the two hospitals are shown in the  
584 supplementary material (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

585

586 We integrated all the obstetrical data, including genotypic and phenotypic data, to  
587 explore the genetic and molecular risk factors underlying the phenotypic spectrum of  
588 pregnant biomarkers. This study was approved by the Medical Ethics Committee of  
589 the School of Public Health (Shenzhen), Sun Yat-sen University, Longgang District  
590 Maternity and Child Healthcare Hospital of Shenzhen City, and Shenzhen Baoan  
591 Women's and Children's Hospital. Data collection was approved by the Human  
592 Genetic Resources Administration of China (HGRAC).

593

#### 594 **Phenotype definition**

595 In the genome-wide association study (GWAS) analyzing gestational phenotypes, we  
596 collected 122 maternal phenotypes in nine categories concerning Blood lipid (N=2),  
597 Glycemic (N=6), Blood routine (N=32), Infection (N=14), Kidney function (N=3),  
598 Liver function (N=8), Thyroid function (N=4), Tang screening (N=16) and NIPT  
599 screening (N=3), as well as three categories including Basic information (N=7),  
600 Gestational disorders (N=21) and Birth outcomes (N=6) (**Supplementary Table 2-3**).  
601 For phenotypes with multiple measurements, we filtered out the record with the  
602 earliest measurement date. In longitudinal genetic analyses, we retained all  
603 measurements of complete blood count (CBC).

604

#### 605 **Genotype imputation from Non-Invasive Prenatal Testing data and** 606 **quality control**

607 NIPT for fetal trisomy by sequencing maternal plasma free DNA (cfDNA) is new  
608 genomic sequencing technology<sup>48</sup>. Large-scale low-pass and mediate-coverage  
609 sequencing data are available through NIPT. In our previous study, we demonstrated  
610 that NIPT data can be used effectively for GWAS analysis<sup>7</sup>. Therefore, it is robust that

611 we use imputed NIPT data for genetic basis of prenatal and postnatal screening  
612 indicators.

613

614 Genotype imputation from NIPT data was conducted by genotype likelihoods  
615 imputation and phasing method using GLIMPSE software (version 1.1.1)<sup>49</sup> with  
616 10,000 Chinese population high-depth sequencing genotype as reference panel<sup>50</sup>. Loci  
617 with minor allele frequency less than 0.001 were filtered in advance for reference  
618 panel. To address confounding by population relatives, we excluded the duplicated  
619 sequencing records of the same people from different pregnant times and kept the  
620 highest sequencing depth.

621

## 622 **Family relatedness and principal component analyses**

623 PLINK<sup>51</sup> (version 2.0) was used to select SNPs with an MAF of at least 5%. The  
624 kinship was calculated based on the KING-robust kinship estimator. We used a cutoff  
625 of approximately 0.354 to identify monozygotic twins and duplicate samples. In  
626 addition, we applied PLINK<sup>51</sup> (version 2.0) for principal component analyses (PCA)  
627 both before and after genotype imputation. EMU<sup>52</sup> (version 0.9) was used for PCA  
628 specifically before genotype imputation.

629

## 630 **Variant annotation**

631 We performed variant annotation using Ensembl Variant Effect Predictor (VEP)  
632 (version 101)<sup>53</sup>, with indexed GRCh38 cache files (version 109). HGVS notations  
633 were generated by primary assembled reference FASTA files for *Homo sapiens*. All  
634 these data for annotation were pre-downloaded from the Ensembl FTP server  
635 (<https://ftp.ensembl.org/pub/>). Since a variant may overlap with multiple transcripts,  
636 we used the --pick option to assign one block of results to each variant based on a set  
637 of VEP default criteria. For variants located in intergenic regions, we used the --



638 nearest option to identify the nearest gene to the protein-coding transcription start site  
639 (TSS).

640

### 641 **Genome-wide association analysis and conditional analysis**

642 After quality control of the sequencing data and imputation of genotype from the  
643 NIPT data, we conducted genome-wide association analysis using PLINK<sup>51</sup> (version  
644 2.0) to examine the association of the 122 phenotypes, assuming additive genotype  
645 effects. For quantitative traits, we utilized linear regression model for GWAS, and for  
646 qualitative traits, we used logistic regression model. To account for population  
647 stratification, we considered some or all the following as covariates in the GWAS for  
648 all phenotypes: maternal age, body mass index (BMI), gestational week at the time of  
649 indicators measurement, and the top ten principal components. All GWAS covariates  
650 were shown in the **Supplementary Table 6**.

651

652 Using the GWAS summary statistics from two hospitals, we performed meta-analyses  
653 using METAL<sup>54</sup> (version 2011-03-25) with an inverse-variance weighted (IVW)  
654 fixed-effect model. To visualize the meta-analyses results, we generated fuji plot  
655 using R script and Circos software<sup>55,56</sup>. Then, we used the GWAS meta summary  
656 statistics for all the subsequent analyses.

657

658 To identify independent genome-wide significant signals ( $P < 5 \times 10^{-8}$ ), we used  
659 GCTA<sup>57</sup> multi-SNP-based conditional & joint association analysis (COJO<sup>18</sup>) with a  
660 stepwise model selection (--cojo-slct). Variants with MAF < 0.01 were filtered and  
661 the collinearity threshold was 0.2. 500kb upstream and downstream block of a  
662 genome-wide significant signal was divided into a separate locus. The SNP with the  
663 smallest  $P$  value in each locus was selected as the lead SNP. In addition, if the SNP  
664 had  $P$  value less than  $4.1 \times 10^{-10}$ , it was considered to be a variant that reached the  
665 study-wide significance. Similarly, we used the same method to select independent

666 SNPs from the 220 GWAS summary statistics of BBJ cohort<sup>10</sup> and 23 GWAS  
667 summary statistics of Taiwan Biobank<sup>19</sup> for subsequent analysis.

668

### 669 **Replication of independent genome-wide significant signals**

670 To examine whether genetic effects of the same phenotype were equivalent between  
671 the two cohorts, we performed internal replication and external comparison of  
672 independent genome-wide significant SNPs obtained from conditional analysis using  
673 two methods. In the internal replication, we compared the direction of beta and  $P$   
674 value of each SNP in the two hospitals. The criteria for a SNP to be replicated were  
675 that it had consistent beta direction and the  $P$  value was less than the Bonferroni-  
676 corrected significant threshold (0.05/number of independent SNPs per phenotype). In  
677 the second approach, based on the central limit theorem, we utilized a *two-sample t-*  
678 *test* with the following hypotheses:

$$\text{Null hypothesis } H_0: \beta_1 = \beta_2$$

$$\text{Alternative hypothesis } H_1: \beta_1 \neq \beta_2$$

679 The statistic  $T$  was calculated as follows:

$$T = \frac{\beta_1 - \beta_2}{\sqrt{SE_1^2 + SE_2^2}} \sim t(v') \quad (1)$$

680 The degrees of freedom  $v'$  were calculated by the formula:

$$v' = \frac{(SE_1^2 + SE_2^2)^2}{\frac{SE_1^4}{n_1 - 1} + \frac{SE_2^4}{n_2 - 1}} \quad (2)$$

681 In the formulas,  $\beta$  represents the estimate of the genetic effect,  $SE$  represents the  
682 standard error of the genetic effect estimate, and  $N$  represents the sample size of trait  
683 in the cohort. The  $P$  value was calculated using the statistic  $T$  and degrees of freedom  
684  $v'$  obtained from the formulas, and the SNP was replicated successfully if the  $P$  value  
685 was greater than 0.05. In addition, we used METAL to estimate heterogeneity tests for  
686 the genetic effects of SNPs between the two hospitals, and  $P$  value  $\geq 0.05$  were taken

687 to indicate that there was no heterogeneity in the genetic effects of the SNP between  
688 the two hospitals.

689

690 We conducted external replication of the identified variants using the NIPT PLUS  
691 pregnancy cohort, which is a data collection of 5,733 individuals who sought maternal  
692 check-ups at Shenzhen Baoan Women's and Children's Hospital (Shenzhen, China)  
693 throughout the entire 40-week gestational period. Between 2020 and 2021, these  
694 pregnant women received NIPT in the first or second trimester and provided written  
695 informed consent. Besides, these samples were sequenced at a deeper depth compared  
696 to traditional NIPT. The genotyping and quality control process of NIPT PLUS cohort  
697 participants were the same as Baoan and Longgang. Among the 122 phenotypes in  
698 this study, 103 phenotypes could be replicated in the NIPT PLUS pregnancy cohort.  
699 We used the same methods as for the internal replication to perform external  
700 replication of the variants for these 103 phenotypes.

701

## 702 **Comparison of genetic effects on maternal height and Taiwanese** 703 **population height**

704 As maternal height is essentially unchanged during pregnancy, we demonstrate the  
705 effectiveness of our GWAS results by comparing the genetic effects of height in the  
706 Taiwanese population with the genetic effects of maternal height related variants<sup>19</sup>.  
707 We extracted genome-wide significant independent variants associated with height in  
708 Taiwanese population and found corresponding genetic effects in our GWAS  
709 summary statistic. Comparisons were made using the Bonferroni correction threshold  
710 method and the rate of success in the comparison was calculated.

711

## 712 **Identification of novel locus and signal**

713 We downloaded all associations (v1.0.2\_e109\_r2023-02-15) from GWAS Catalog<sup>20</sup>  
714 to identify novel associated SNPs. A trait associated locus was considered novel when

715 the  $\pm 500$ kb range of the lead SNP did not include previously reported associations in  
716 the GWAS Catalog for the same trait. In addition, we considered a trait-associated  
717 signal as novel when it satisfied that the  $R^2$  between the GWAS Catalog reported  
718 SNPs and our SNP was less than 0.2. The  $R^2$  calculations were performed on the  
719 LDpair Tool through LDlink<sup>58</sup> (version 5.5.1) based on GRCh38 1000G genome build  
720 in the EAS and EUR populations.

721

### 722 **Protein-protein interaction network analysis**

723 We selected genes hosting loci in our study for protein-protein interaction (PPI)  
724 analysis. Genes with PPI score  $> 0.4$  were chosen to build a network model visualized  
725 by Cytoscape (Version:3.10.1)<sup>59</sup>. The degree algorithm implemented in CytoHubba<sup>60</sup>  
726 was used to compute the top 10 hub genes. Software parameters used default  
727 parameters.

728

### 729 **Genetic heritability and correlation estimates**

730 We standardized the phenotypic data and calculated their Spearman correlation  
731 coefficients to obtain the phenotypic correlation matrix. Then the meta GWAS  
732 summary statistics were used to estimate SNP-based heritability and genetic  
733 correlation ( $r_g$ ) for all phenotypes using LD Score Regression<sup>33,61</sup>. GCTA<sup>62</sup> was used  
734 to calculate LD score files using 10,000 Chinese population high-depth sequencing  
735 genotype. The genome was chopped into segments with length of 1000kb (--ld-wind  
736 1000), and the cutoff for LD  $R^2$  was 0.01 (--ld-rsq-cutoff 0.01). The phenotypic  
737 correlation matrix and genetic association matrix of the two hospitals were extracted  
738 to draw heat maps, respectively.

739

### 740 **Detection of pregnancy-specific effects**

741 Because of the paucity of currently available GWAS summary statistics for pregnancy  
742 and the influence of population structure, we used GWAS summary statistics for

743 similar phenotypes from the Taiwan Biobank<sup>19</sup>, which were downloaded for external  
744 comparisons. Three conditions were required for an independent SNP to be compared:  
745 1) the SNP was present in the externally compared GWAS summary statistic; 2) the  
746 effect allele and the direction of the genetic effect were the same as those of the  
747 externally data; and 3) the  $P$  value was less than the Bonferroni-corrected threshold  
748 (0.05/number of loci).

749

750 We applied `linemodels` package<sup>36</sup> (<https://github.com/mjpirinen/linemodels>) to the  
751 GWAS summary statistics from gestational phenotypes GWAS and similar  
752 phenotypes GWAS in the general population of East Asia. The analysis included  
753 1,318 variants in 23 phenotypes (**Supplementary Table 23**). We classified the  
754 variants into two clusters based on their effect sizes, pregnancy specific variants and  
755 general variants. If the genetic effect of the variant is more different from that of the  
756 general population in East Asia, it is called a pregnancy specific variant (posterior  
757 probability of pregnancy > 0.95), and if the genetic effect is more consistent between  
758 the two, it is called a general variant (posterior probability of general > 0.95). The  
759 clusters were represented by line models where the slope of the pregnancy cluster is  
760 fixed to 0, the correlations are fixed to 0.999 in both clusters, and the other parameters  
761 are estimated using EM algorithm. The parameters of the various categories are  
762 shown in **Supplementary Table 23**. The slope represents the slopes of the two lines,  
763 and the scale determines the magnitude of effect sizes, and the correlation determines  
764 the allowed deviation from the lines.

765

766 To exclude the effect of LD structure on classification, we performed colocalization  
767 analyses of variants in gestational phenotypes and variants in East Asian populations  
768 with the same or similar phenotypes and adjusted the `linemodels` results depending on  
769 colocalization results. We set the prior probability of an SNP associated with  
770 phenotypes of pregnant women ( $p_1$ ) and in East Asia ( $p_2$ ) as  $1 \times 10^{-4}$ , and the prior

771 probability of an SNP associated with both traits ( $p_{12}$ ) as  $5 \times 10^{-6}$ <sup>63</sup>. We adjusted the  
772 classification results by adopting the following criteria. If a variant classified as a  
773 pregnancy cluster in line models had a posterior probability (PPH4) < 0.2, the  
774 classification result remained unchanged; otherwise, it was classified as an uncertain  
775 cluster; if a variant in a general cluster had a PPH4 > 0.8, the classification result  
776 remained unchanged; otherwise, it was classified as an uncertain cluster; if a variant  
777 classified as a uncertain cluster in line models had a PPH4 < 0.2, it was classified as  
778 an pregnancy cluster; if a variant classified as a uncertain cluster in line models had a  
779 PPH4 > 0.8, it was classified as an general cluster. The results of the classification of  
780 the other cases are consistent with line models.

781

## 782 **Enrichment analysis of variants**

783 Based on the results of line models, we performed enrichment analysis using  
784 Metascape (v3.5.20240101)<sup>64</sup>. This method calculates the hit rate with our gene list  
785 and the background hit rate based on the number of genes in each section, and the  
786 ratio of the two is the enrichment factor. The *P*-value is defined as the probability of  
787 obtaining multiple pathways, forming a cumulative hypergeometric distribution, the  
788 more negative the value, the less likely it is that the observed enrichment is due to  
789 randomness. The analysis was performed with default parameters, namely, the min  
790 overlap was set to 3, the *P* value cutoff was 0.01, the min enrichment factor was 1.5.  
791 Ontology category included GO Biological Processes, Reactome Gene Sets, KEGG  
792 Pathway, WikiPathways, Canonical Pathways and PANTHER Pathway.

793

794 We performed separate enrichment analyses for genes with pregnancy-specific  
795 variants and genes with general variants, selecting the top 20 pathways with the most  
796 significant pregnancy-specific variants and comparing them with the general variants.  
797 We also aggregated all genes for enrichment analysis of single gene lists.

798

## 799 Longitudinal trajectories of genetic effects

800 We conducted analyses using TrajGWAS<sup>39</sup> to identify genetic variants that contribute  
801 to change in gestational phenotypes during pregnancy and postpartum. We used  
802 gestational day as a time factor to determine whether there was a genetic-time  
803 interaction. GWAS for longitudinal biomarkers was performed using the TrajGWAS  
804 method, based on a mixed effects model with the following formula:

$$y_{ij} = x_{ij}\beta + g_i\beta_g + G \times T \times \beta_{G \times T} + \varepsilon_{ij} \quad (3)$$

805  $y_{ij}$  represents the phenotypic value of the  $j$ th measurement for the  $i$ th pregnant  
806 woman.  $x_{ij}$  represents fixed-effects covariates, including the first ten principal  
807 components, maternal age and gestational days at phenotypic testing,  $\beta$  is its  
808 corresponding effect value.  $g_i$  denotes the genotype dosage for the  $i$ th pregnant  
809 woman, corresponding to a genetic effect of  $\beta_g$ .  $G \times T$  represents the interaction  
810 between maternal genotype dosage and gestational time, corresponding to an effect  
811 value of  $\beta_{G \times T}$ .  $\varepsilon_{ij}$  is a random-effects term reflecting the variance of the genetic  
812 variants affecting the within-subject (WS) variance of the biomarker. The formula for  
813 the variance  $\sigma_{\varepsilon_{ij}}^2$  of  $\varepsilon_{ij}$  is given below:

$$\sigma_{\varepsilon_{ij}}^2 = \exp(\tau w_{ij} + \tau_g g_i + \tau_{G \times T} G \times T + \omega_i) \quad (4)$$

814  $w_{ij}$  is a covariate including the first 10 principal components, maternal age, and  
815 gestational days at phenotypic measurement, and  $\tau$  is the corresponding effect value.  
816  $\tau_g$  denotes the genetic effect affecting the variance of WS.  $\tau_{G \times T}$  indicates the effect  
817 value for the interaction of maternal genotype dosage and gestational time.  $\omega_i$  denotes  
818 the random intercept.

819

820 There were 24 of these phenotypes, involving phenotypes of the Blood routine  
821 categories (N=24). Specific phenotypes are shown in **Supplementary Table 27**.  
822 Following the procedure described by Ko et al., we first performed the score test for  
823 SNPs, obtaining the direction of the effect ( $\beta_g$  or  $\tau_g$ ) and the  $P$  value that affected the  
824 mean and within-subject variability for each phenotype. Subsequently, the Wald test

825 was performed on SNPs with a  $P$  value of  $\beta_g$  or  $\tau_g$  less than  $5 \times 10^{-8}$  to estimate the  
826 effect sizes of the genetic effect of genotype dosage ( $\beta_g$  or  $\tau_g$ ) and the effect of  
827 interaction between maternal genotype dosage and gestational time ( $\beta_{G \times T}$  or  $\tau_{G \times T}$ ).  
828 Subsequently, we performed a meta-analysis of the effect values of these significant  
829 SNPs using METAL<sup>54</sup>. TrajGWAS analyses were performed with the Julia package  
830 TrajGWAS.jl (<https://github.com/OpenMendel/TrajGWAS.jl>)<sup>65</sup>. Manhattan and QQ  
831 plots in the supplementary figures were drawn with a Julia package MendelPlots.jl  
832 (<https://github.com/OpenMendel/MendelPlots.jl>)<sup>65</sup> with SNP minor allele  
833 frequency > 0.01. To identify independent significant loci, we used a python script  
834 where the variant with the smallest  $P$  value in the 1Mb range was the lead SNP, and  
835 variants within 500kb above and below the lead variant were classified into a locus.

836

837 In order to investigate whether the genetic effects of the loci identified by TrajGWAS  
838 change during a total of five periods: first, second, and third trimester of pregnancy,  
839 day of delivery, and within 42 days postpartum, we performed localized association  
840 analyses of these loci. The main steps were consistent with the previous GWAS,  
841 except that the PLINK<sup>51</sup> (version 2.0) parameters --chr, --from-bp, and --to-bp were  
842 used to point to the loci. We defined a variant with change as a non-overlapping 95%  
843 confidence interval (CI) for the genetic effect in at least two of the five periods.

844

845 We enriched the variants with significant genotype dosage for significant and non-  
846 significant interactions between genetics and environment. Methods were the same as  
847 for the enrichment analyses described above.

848

## 849 **Mendelian randomization network of pregnancy, Taiwanese and** 850 **BBJ traits**

851 To identify whether pregnancy status affects the development of future disease  
852 progression, bidirectional mendelian randomization analyses were performed on



853 cohort of this study and Japanese Biobank cohort data with the TwoSampleMR  
854 package<sup>66,67</sup>. We used GWAS summary statistics from two cohorts and independent  
855 SNPs obtained from GCTA-COJO as genetic instruments ( $P < 5 \times 10^{-8}$ ) in our MR  
856 analyses. We also calculated the proportion of variance in phenotypes explained (PVE)  
857 by the instruments according to the formula<sup>68</sup> (3) and calculated the F-statistic  
858 according to formula (4) to evaluate the strength of instruments, with  $F$  values greater  
859 than 10 indicating sufficient strength.

$$PVE = \frac{2\hat{\beta}^2 MAF(1 - MAF)}{2\hat{\beta}^2 MAF(1 - MAF) + (se(\hat{\beta}))^2 2NMAF(1 - MAF)} \quad (5)$$

$$F = \frac{N - nsnp - 1}{nsnp} \times \frac{PVE}{1 - PVE} \quad (6)$$

860 The assessments of the instrumental variables are shown in the **Supplementary**  
861 **Table 36-39**. We conducted sensitivity analyses using alternative MR methods that  
862 including: 1) MR Egger; 2) Simple mode; 3) Weighted median; 4) Weighted mode.  
863 Among the several methods of MR analyses, the inverse variance weight (IVW)  
864 method which confers the greatest statistical power for estimating causal associations  
865 was used as primary reference<sup>69</sup>.

866

867 To examine and address horizontal pleiotropy in causal relationships inferred from  
868 MR analyses, we performed MR-PRESSO<sup>40</sup> using the results of the first two-sample  
869 MR. The outliers were found using MR-PRESSO and tested for differences between  
870 the pre-correction and post-correction results. The outliers would be excluded, and the  
871 two-sample MR was performed again if the difference was significant.

872

873 Robust causal estimates were defined as those that were significant at FDR  $q$  value of  
874 IVW<sup>70</sup> ( $q < 0.01$ ) and showed no evidence of heterogeneity ( $P > 0.05$ ) and horizontal  
875 pleiotropy ( $P > 0.05$ ) after MR-PRESSO.

876

877 We also performed two-sample MR of 23 Taiwanese phenotypes with 220 BBJ  
878 phenotypes. The methodology is the same as in the previous section. Genetic  
879 instrumental variable information is displayed in **Supplementary Table 43-44**.

880

881 To adjust for the influence of mid-life health status on causal relationships, we  
882 incorporated 23 phenotypes from the Taiwan Biobank<sup>19</sup> as a second exposure in the  
883 multivariable mendelian randomization analysis<sup>71,72</sup>. The gestational phenotype and  
884 the Taiwan Biobank phenotype were used as exposures, and the 220 phenotypes from  
885 the BBJ were used as outcomes. We also used the TwoSampleMR package. The  
886 significance threshold is  $q < 0.01$ .

887

888

889

890

891

892

893

## 894 Reference

- 895 1. Stock, S.J. & Aiken, C.E. Barriers to progress in pregnancy research: How can  
896 we break through? *Science* **380**, 150-153 (2023).
- 897 2. Qiao, J. *et al.* A Lancet Commission on 70 years of women's reproductive,  
898 maternal, newborn, child, and adolescent health in China. *Lancet* **397**, 2497-  
899 2536 (2021).
- 900 3. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE),  
901 and population estimates in 204 countries and territories, 1950-2019: a  
902 comprehensive demographic analysis for the Global Burden of Disease Study  
903 2019. *Lancet* **396**, 1160-1203 (2020).
- 904 4. Chen, X. *et al.* The path to healthy ageing in China: a Peking University-  
905 Lancet Commission. *Lancet* **400**, 1967-2006 (2022).
- 906 5. Yu, D. *et al.* A multi-tissue metabolome atlas of primate pregnancy. *Cell* **187**,  
907 764-781.e14 (2024).
- 908 6. Hunter, P.J. *et al.* Biological and pathological mechanisms leading to the birth  
909 of a small vulnerable newborn. *Lancet* **401**, 1720-1732 (2023).
- 910 7. Liu, S. *et al.* Genomic Analyses from Non-invasive Prenatal Testing Reveal  
911 Genetic Associations, Patterns of Viral Infections, and Chinese Population  
912 History. *Cell* **175**, 347-359.e14 (2018).
- 913 8. Zhen, J. *et al.* Genome-wide association and Mendelian randomisation  
914 analysis among 30,699 Chinese pregnant women identifies novel genetic and  
915 molecular risk factors for gestational diabetes and glycaemic traits.  
916 *Diabetologia* **67**, 703-713 (2024).
- 917 9. Yang, Z. *et al.* Genetic Basis of Altered Platelet Counts and Gestational  
918 Thrombocytopenia in Pregnancy. *Blood* (2023).
- 919 10. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220  
920 human phenotypes. *Nat Genet* **53**, 1415-1424 (2021).

- 921 11. Graham, S.E. *et al.* The power of genetic diversity in genome-wide association  
922 studies of lipids. *Nature* **600**, 675-679 (2021).
- 923 12. Elliott, A. *et al.* Distinct and shared genetic architectures of gestational  
924 diabetes mellitus and type 2 diabetes. *Nat Genet* **56**, 377-382 (2024).
- 925 13. Juliusdottir, T. *et al.* Distinction between the effects of parental and fetal  
926 genomes on fetal growth. *Nat Genet* **53**, 1135-1142 (2021).
- 927 14. Huang, S. *et al.* The Born in Guangzhou Cohort Study enables generational  
928 genetic discoveries. *Nature* **626**, 565-573 (2024).
- 929 15. Mitha, A. *et al.* Neurological development in children born moderately or late  
930 preterm: national cohort study. *Bmj* **384**, e075630 (2024).
- 931 16. Crump, C. *et al.* Adverse pregnancy outcomes and long term risk of ischemic  
932 heart disease in mothers: national cohort and co-sibling study. *Bmj* **380**,  
933 e072112 (2023).
- 934 17. Liu, S. *et al.* Utilizing Non-Invasive Prenatal Test Sequencing Data Resource  
935 for Human Genetic Investigation. *bioRxiv*, 2023.12. 11.570976 (2023).
- 936 18. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS  
937 summary statistics identifies additional variants influencing complex traits.  
938 *Nat Genet* **44**, 369-75, s1-3 (2012).
- 939 19. Chen, C.Y. *et al.* Analysis across Taiwan Biobank, Biobank Japan, and UK  
940 Biobank identifies hundreds of novel loci for 36 quantitative traits. *Cell*  
941 *Genom* **3**, 100436 (2023).
- 942 20. Sallis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and  
943 deposition resource. *Nucleic Acids Res* **51**, D977-d985 (2023).
- 944 21. Kelleher, A.M., DeMayo, F.J. & Spencer, T.E. Uterine Glands:  
945 Developmental Biology and Functional Roles in Pregnancy. *Endocr Rev* **40**,  
946 1424-1445 (2019).
- 947 22. Mills, M.C. *et al.* Identification of 371 genetic variants for age at first sex and  
948 birth linked to externalising behaviour. *Nat Hum Behav* **5**, 1717-1730 (2021).

- 949 23. Gibson, D.A. *et al.* Profiling the expression and function of oestrogen receptor  
950 isoform ER46 in human endometrial tissues and uterine natural killer cells.  
951 *Hum Reprod* **35**, 641-651 (2020).
- 952 24. Schlaikjær Hartwig, T. *et al.* Cell-free fetal DNA for genetic evaluation in  
953 Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.  
954 *Lancet* **401**, 762-771 (2023).
- 955 25. Chitty, L.S. Use of cell-free DNA to screen for Down's syndrome. *N Engl J*  
956 *Med* **372**, 1666-7 (2015).
- 957 26. Wang, W. *et al.* Homozygous variants in PANX1 cause human oocyte death  
958 and female infertility. *Eur J Hum Genet* **29**, 1396-1404 (2021).
- 959 27. Sang, Q. *et al.* A pannexin 1 channelopathy causes human oocyte death. *Sci*  
960 *Transl Med* **11**(2019).
- 961 28. Brinkmann, V. *et al.* Neutrophil extracellular traps kill bacteria. *Science* **303**,  
962 1532-5 (2004).
- 963 29. Bouvier, S. *et al.* NETosis Markers in Pregnancy: Effects Differ According to  
964 Histone Subtypes. *Thromb Haemost* **121**, 877-890 (2021).
- 965 30. Guillotin, F. *et al.* Vital NETosis vs. suicidal NETosis during normal  
966 pregnancy and preeclampsia. *Front Cell Dev Biol* **10**, 1099038 (2022).
- 967 31. Yu, G. *et al.* APRIL and TALL-I and receptors BCMA and TACI: system for  
968 regulating humoral immunity. *Nat Immunol* **1**, 252-6 (2000).
- 969 32. Duan, T. *et al.* USP3 plays a critical role in the induction of innate immune  
970 tolerance. *EMBO Rep* **24**, e57828 (2023).
- 971 33. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding  
972 from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5  
973 (2015).
- 974 34. lab, N. UK Biobank-Neale lab. (2018).
- 975 35. Dalmia, A. *et al.* A genetic epidemiological study in British adults and older  
976 adults shows a high heritability of the combined indicator of vitamin B(12)

- 977 status (cB(12)) and connects B(12) status with utilization of mitochondrial  
978 substrates and energy metabolism. *J Nutr Biochem* **70**, 156-163 (2019).
- 979 36. Pirinen, M. linemodls: clustering effects based on linear relationships.  
980 *Bioinformatics* **39**(2023).
- 981 37. Li, A., Yang, S., Zhang, J. & Qiao, R. Establishment of reference intervals for  
982 complete blood count parameters during normal pregnancy in Beijing. *J Clin*  
983 *Lab Anal* **31**(2017).
- 984 38. Zhu, J., Li, Z., Deng, Y., Lan, L. & Yang, J. Comprehensive reference  
985 intervals for white blood cell counts during pregnancy. *BMC Pregnancy*  
986 *Childbirth* **24**, 35 (2024).
- 987 39. Ko, S. *et al.* GWAS of longitudinal trajectories at biobank scale. *Am J Hum*  
988 *Genet* **109**, 433-445 (2022).
- 989 40. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread  
990 horizontal pleiotropy in causal relationships inferred from Mendelian  
991 randomization between complex traits and diseases. *Nat Genet* **50**, 693-698  
992 (2018).
- 993 41. Bonaca, M.P., Hamburg, N.M. & Creager, M.A. Contemporary Medical  
994 Management of Peripheral Artery Disease. *Circ Res* **128**, 1868-1884 (2021).
- 995 42. Ranaei Pirmardan, E. *et al.* Pre-hyperglycemia immune cell trafficking  
996 underlies subclinical diabetic cataractogenesis. *J Biomed Sci* **30**, 6 (2023).
- 997 43. Jonasson, L., Tompa, A. & Wikby, A. Expansion of peripheral CD8+ T cells  
998 in patients with coronary artery disease: relation to cytomegalovirus infection.  
999 *J Intern Med* **254**, 472-8 (2003).
- 1000 44. Borgia, M.C. *et al.* Further evidence against the implication of active  
1001 cytomegalovirus infection in vascular atherosclerotic diseases. *Atherosclerosis*  
1002 **157**, 457-62 (2001).
- 1003 45. Parikh, N.I. *et al.* Adverse Pregnancy Outcomes and Cardiovascular Disease  
1004 Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women:

- 1005 A Scientific Statement From the American Heart Association. *Circulation* **143**,  
1006 e902-e916 (2021).
- 1007 46. Auger, N., Tang, T., Healy-Profítós, J. & Paradis, G. Gestational diabetes and  
1008 the long-term risk of cataract surgery: A longitudinal cohort study. *J Diabetes*  
1009 *Complications* **31**, 1565-1570 (2017).
- 1010 47. Patel, R.R., Steer, P., Doyle, P., Little, M.P. & Elliott, P. Does gestation vary  
1011 by ethnic group? A London-based study of over 122,000 pregnancies with  
1012 spontaneous onset of labour. *Int J Epidemiol* **33**, 107-113 (2004).
- 1013 48. Cheung, S.W., Patel, A. & Leung, T.Y. Accurate description of DNA-based  
1014 noninvasive prenatal screening. *N Engl J Med* **372**, 1675-7 (2015).
- 1015 49. Rubinacci, S., Ribeiro, D.M., Hofmeister, R.J. & Delaneau, O. Efficient  
1016 phasing and imputation of low-coverage sequencing data using large reference  
1017 panels. *Nature Genetics* **53**, 120-126 (2021).
- 1018 50. Cheng, S. *et al.* The STROMICS genome study: deep whole-genome  
1019 sequencing and analysis of 10K Chinese patients with ischemic stroke reveal  
1020 complex genetic and phenotypic interplay. *Cell Discov* **9**, 75 (2023).
- 1021 51. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger  
1022 and richer datasets. *Gigascience* **4**, 7 (2015).
- 1023 52. Meisner, J., Liu, S., Huang, M. & Albrechtsen, A. Large-scale inference of  
1024 population structure in presence of missingness using PCA. *Bioinformatics* **37**,  
1025 1868-1875 (2021).
- 1026 53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**,  
1027 122 (2016).
- 1028 54. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis  
1029 of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 1030 55. Krzywinski, M. *et al.* Circos: an information aesthetic for comparative  
1031 genomics. *Genome Res* **19**, 1639-45 (2009).

- 1032 56. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese  
1033 population links cell types to complex human diseases. *Nat Genet* **50**, 390-400  
1034 (2018).
- 1035 57. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: A Tool for  
1036 Genome-wide Complex Trait Analysis. *The American Journal of Human*  
1037 *Genetics* **88**, 76-82 (2011).
- 1038 58. Machiela, M.J. & Chanock, S.J. LDlink: a web-based application for exploring  
1039 population-specific haplotype structure and linking correlated alleles of  
1040 possible functional variants. *Bioinformatics* **31**, 3555-7 (2015).
- 1041 59. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of  
1042 biomolecular interaction networks. *Genome Res* **13**, 2498-504 (2003).
- 1043 60. Chin, C.-H. *et al.* cytoHubba: identifying hub objects and sub-networks from  
1044 complex interactome. *BMC Systems Biology* **8**, S11 (2014).
- 1045 61. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases  
1046 and traits. *Nat Genet* **47**, 1236-41 (2015).
- 1047 62. Yang, J. *et al.* Genetic variance estimation with imputed variants finds  
1048 negligible missing heritability for human height and body mass index. *Nat*  
1049 *Genet* **47**, 1114-20 (2015).
- 1050 63. Wallace, C. Eliciting priors and relaxing the single causal variant assumption  
1051 in colocalisation analyses. *PLoS Genet* **16**, e1008720 (2020).
- 1052 64. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the  
1053 analysis of systems-level datasets. *Nat Commun* **10**, 1523 (2019).
- 1054 65. Zhou, H. *et al.* OPENMENDEL: a cooperative programming project for  
1055 statistical genetics. *Hum Genet* **139**, 61-71 (2020).
- 1056 66. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference  
1057 across the human phenome. *eLife* **7**(2018).



- 1058 67. Li, J., Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal  
1059 relationship between imprecisely measured traits using GWAS summary data.  
1060 *PLOS Genetics* **13**(2017).
- 1061 68. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci  
1062 for blood lipids. *Nature* **466**, 707-13 (2010).
- 1063 69. Slob, E.A.W. & Burgess, S. A comparison of robust Mendelian randomization  
1064 methods using summary data. *Genetic Epidemiology* **44**, 313-329 (2020).
- 1065 70. John D. Storey, A.J.B., Alan Dabney, David Robinson. qvalue: Q-value  
1066 estimation for false discovery rate control. R package version 2.36.0 (2024).
- 1067 71. Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold  
1068 Spring Harb Perspect Med* **11**(2021).
- 1069 72. Vabistsevits, M. Setting up Multivariable Mendelian Randomization analysis  
1070 in R. (22 March, 2021).
- 1071
- 1072

## 1073 **Figure Legends**

### 1074 **Figure 1. Schematic overview of the study.**

1075 We curated a comprehensive dataset comprising 122 pregnancy-related phenotypes  
1076 from 120,579 Chinese pregnant women. We conducted an in-depth analysis of the  
1077 genetic architecture underlying these phenotypes, identified biological pathways  
1078 enriched for genetic variants, and explored genetic variants associated with alterations  
1079 in the longitudinal trajectories of these phenotypes. Additionally, we investigated  
1080 potential causal relationships between gestational phenotypes and various diseases.

1081

### 1082 **Figure 2. Genetic associations with nine categories of gestational** 1083 **phenotypes.**

1084 The top-left inset presents a histogram depicting the number of loci associated with  
1085 gestational phenotypes for each trait, categorized into novel and known loci. In the  
1086 main panel, a Fuji plot illustrates the results of the genome-wide association analysis  
1087 (GWAS) across all phenotypes within nine categories. Independent variants identified  
1088 through meta-analysis ( $P < 4.1 \times 10^{-10}$ ) are shown. The number of associated  
1089 phenotypes per pleiotropic locus is represented by filled colored boxes, with  
1090 functional and newly discovered loci labeled directly on the plot. Detailed information  
1091 on functional loci can be found in Supplementary Table 15. Pleiotropic and trait-  
1092 specific associations are distinguished by circles of varying sizes. The order of the 88  
1093 gestational phenotypes in both the histogram and Fuji plot corresponds to that in  
1094 Supplementary Table 2.

1095

### 1096 **Figure 3. Classification of the genetic effects of SNPs on gestational** 1097 **phenotypes and Taiwan Biobank phenotypes, along with the** 1098 **identification of pathways enriched for pregnancy specific and** 1099 **general variants.**

1100 Panel **A** presents a plot classifying the genetic effects of SNPs ( $P < 4.1 \times 10^{-10}$ ,  
1101 Bonferroni correction threshold) on gestational phenotypes, utilizing a Bayesian  
1102 classification algorithm and colocalization analysis. Panel **B** features a butterfly bar  
1103 plot illustrating the top 20 most significant pathways for pregnancy-specific variants,  
1104 identified through Metascape enrichment analysis. On the left side, the plot shows the  
1105 enrichment  $P$  values for pregnancy-specific variants and the percentage of genes  
1106 enriched in each pathway relative to the total number of pregnancy-specific genes.  
1107 The right side displays the corresponding results for general variants. Pathways  
1108 showing significant differences in gene enrichment, as determined by a chi-square test,  
1109 are marked with an asterisk (\*).

1110

1111 **Figure 4. Results of trajectory changes in blood cell traits during**  
1112 **pregnancy.**

1113 Panel **A** presents forest plots illustrating the genetic effects across five time periods  
1114 with significant genetic and environmental interactions for the first 25 variants, as  
1115 well as for at least two of the five periods where no overlap in genetic effects was  
1116 observed. Different colors represent each period, indicating beta values and 95%  
1117 confidence intervals, with annotations highlighting whether the variant has a  $P$ -value  
1118 less than  $5 \times 10^{-8}$ . The eQTL status of each variant is indicated adjacent to the  
1119 variant label. Detailed information can be found in Supplementary Table 31. Panel **B**  
1120 depicts changes in white blood cell (WBC) counts across the first, second, and third  
1121 trimesters, at delivery, and during the postpartum period, based on data from two  
1122 hospitals. A generalized additive model was used to smooth the curve, with the ribbon  
1123 around the curve representing the 95% confidence interval. The first trimester spans  
1124 from conception to 14 weeks (98 days), the second trimester covers weeks 14 through  
1125 28 (196 days), and the third trimester extends from week 28 to delivery. Panel **C**  
1126 displays a forest plot of the genetic effect of the rs2270401-A allele at 17q21.1  
1127 (*MED24*) on WBC counts, based on a meta-analysis across the first, second, and third

1128 trimesters, at delivery, and postpartum. Points represent the genetic effect (beta), with  
1129 error bars indicating the 95% confidence interval. Panel **D** presents the results of  
1130 enrichment analyses for variants showing significant and non-significant genetic and  
1131 environmental interactions.


1132 BASO: basophil absolute value; BASO\_P: basophil percentage; HGB: hemoglobin  
1133 level; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;  
1134 RDW\_CV: red blood cell volume distribution width variation; PLT: platelet count;  
1135 MPV: mean platelet volume; PCT: platelet crit; PDW: platelet distribution width;  
1136 P\_LCR: platelet-large cell ratio.

1137

1138 **Figure 5. Causal inferences between pregnancy-related phenotypes**  
1139 **and BBJ phenotypes.**

1140 Panel **A** displays bidirectional Mendelian Randomization (MR) estimates, illustrating  
1141 causal links between all pregnancy-related phenotypes (blue nodes) and traits from  
1142 the Biobank Japan (BBJ) cohort (red nodes). Arrows indicate the direction of  
1143 association, with red denoting an increasing effect and blue representing a decreasing  
1144 effect. Panel **B** features a heatmap of MR results, showing nine categories of  
1145 gestational phenotypes as the exposures (right) and BBJ phenotypes as the outcomes  
1146 (bottom). Relationships with  $P$  values below the false discovery rate (FDR) threshold  
1147 are annotated with an asterisk (\*,  $q < 0.01$ ). Panel **C** presents an MR scatterplot  
1148 where maternal triglyceride (TG) levels serve as the exposure and the use of  
1149 antithrombotic agents in the BBJ cohort as the outcome. Panel **D** shows an MR  
1150 scatterplot with maternal oral glucose tolerance test 1-hour plasma glucose (OGTT1H)  
1151 levels as the exposure, and peripheral artery disease in the BBJ cohort as the outcome.

# Study Cohort



## Genotype

Genome sequencing from NIPT  
N=121,579




## Phenotypes

Blood lipid & Glycemic (N=8)  
Blood routine (N=32)  
Infection (N=14)  
Liver, Kidney & Thyroid function (N=15)  
Tang & NIPT screen (N=19)

Basic information (N=7)  
Birth outcome (N=6)  
Gestational disorders (N=21)

# Genetic association



Genome-wide association study


24 gestational phenotypes with multiple measurements in 5 periods



GWAS of longitudinal trajectories


# Post-GWAS

## Heritability & Correlation




LDSC  
Up to 44% heritability

## Different variant analysis



Genetic difference



## Mendelian randomization



TwoSample MR & Multivariable MR  
Future health

- Pleiotropic association
- Trait-specific association

Type of loci  
 Known loci  
 Novel loci




MTCP1  
 FAM3A  
 NAA10  
 BCORL1  
 SCO2  
 PACSIN2  
 SEPTIN3  
 FAM227A  
 IGLV3-21  
 CRKL  
 PDXK  
 PSMG1  
 C21orf62-AS1  
 KRTAP21-3  
 N6AMT1  
 C21orf91  
 PRELID3B  
 ZNF217  
 C6orf87  
 C6orf88  
 TIMM50  
 GCGD10  
 QSOX1  
 RPLP0  
 RPLP2  
 RPLP3  
 RPLP4  
 RPLP5  
 RPLP6  
 RPLP7  
 RPLP8  
 RPLP9  
 RPLP10  
 RPLP11  
 RPLP12  
 RPLP13  
 RPLP14  
 RPLP15  
 RPLP16  
 RPLP17  
 RPLP18  
 RPLP19  
 RPLP20  
 RPLP21  
 RPLP22  
 RPLP23  
 RPLP24  
 RPLP25  
 RPLP26  
 RPLP27  
 RPLP28  
 RPLP29  
 RPLP30  
 RPLP31  
 RPLP32  
 RPLP33  
 RPLP34  
 RPLP35  
 RPLP36  
 RPLP37  
 RPLP38  
 RPLP39  
 RPLP40  
 RPLP41  
 RPLP42  
 RPLP43  
 RPLP44  
 RPLP45  
 RPLP46  
 RPLP47  
 RPLP48  
 RPLP49  
 RPLP50  
 RPLP51  
 RPLP52  
 RPLP53  
 RPLP54  
 RPLP55  
 RPLP56  
 RPLP57  
 RPLP58  
 RPLP59  
 RPLP60  
 RPLP61  
 RPLP62  
 RPLP63  
 RPLP64  
 RPLP65  
 RPLP66  
 RPLP67  
 RPLP68  
 RPLP69  
 RPLP70  
 RPLP71  
 RPLP72  
 RPLP73  
 RPLP74  
 RPLP75  
 RPLP76  
 RPLP77  
 RPLP78  
 RPLP79  
 RPLP80  
 RPLP81  
 RPLP82  
 RPLP83  
 RPLP84  
 RPLP85  
 RPLP86  
 RPLP87  
 RPLP88  
 RPLP89  
 RPLP90  
 RPLP91  
 RPLP92  
 RPLP93  
 RPLP94  
 RPLP95  
 RPLP96  
 RPLP97  
 RPLP98  
 RPLP99  
 RPLP100


LIFR-AS1  
 FCHO2  
 IQGAP2  
 ELL2  
 SLC12A2  
 DIAPH1  
 NSD1  
 H4C5  
 ZNF184  
 ZBED9  
 LINC02829  
 HLA-DQB1  
 IP6K3  
 STK38  
 GLP1R  
 BYSL  
 CGA  
 ESR1  
 PRR15-DT  
 GCK  
 CCM2  
 CYP3A7  
 SND1  
 MNX1  
 DYNC211  
 MSRT  
 CCDC25  
 SLC30A8  
 EFF1D  
 BUCK8  
 INSL4  
 SLC35D2  
 ABO  
 FAEP  
 AKR1C4  
 SLC35D2  
 ACSL5  
 HRDC2  
 BRM115  
 KMT1L15  
 KMT1L15  
 FADS1  
 FADS2  
 FADS3  
 FADS4  
 FADS5  
 FADS6  
 FADS7  
 FADS8  
 FADS9  
 FADS10  
 FADS11  
 FADS12  
 FADS13  
 FADS14  
 FADS15  
 FADS16  
 FADS17  
 FADS18  
 FADS19  
 FADS20  
 FADS21  
 FADS22  
 FADS23  
 FADS24  
 FADS25  
 FADS26  
 FADS27  
 FADS28  
 FADS29  
 FADS30  
 FADS31  
 FADS32  
 FADS33  
 FADS34  
 FADS35  
 FADS36  
 FADS37  
 FADS38  
 FADS39  
 FADS40  
 FADS41  
 FADS42  
 FADS43  
 FADS44  
 FADS45  
 FADS46  
 FADS47  
 FADS48  
 FADS49  
 FADS50  
 FADS51  
 FADS52  
 FADS53  
 FADS54  
 FADS55  
 FADS56  
 FADS57  
 FADS58  
 FADS59  
 FADS60  
 FADS61  
 FADS62  
 FADS63  
 FADS64  
 FADS65  
 FADS66  
 FADS67  
 FADS68  
 FADS69  
 FADS70  
 FADS71  
 FADS72  
 FADS73  
 FADS74  
 FADS75  
 FADS76  
 FADS77  
 FADS78  
 FADS79  
 FADS80  
 FADS81  
 FADS82  
 FADS83  
 FADS84  
 FADS85  
 FADS86  
 FADS87  
 FADS88  
 FADS89  
 FADS90  
 FADS91  
 FADS92  
 FADS93  
 FADS94  
 FADS95  
 FADS96  
 FADS97  
 FADS98  
 FADS99  
 FADS100

**A**

Gestational phenotypes

**B**

-LogP of pregnancy specific variants



-LogP of general variants

